ID

32957

Description

This form contains a form to document the results of the electronically transferred lab data. To be assessed at screening, follow-up and where required early withdrawal visit. Study ID: 103629 Clinical Study ID: TRX103629 Study Title: An open-label, randomized, 3-period crossover study to evaluate sumatriptan and naproxen pharmacokinetics for a combination tablet product containing sumatriptan/naproxen sodium followed by IMITREX™ (sumatriptan succinate) Injection 4mg administered using the IMITREX STATdose System and a sumatriptan/naproxen sodium tablet followed by IMITREX (sumatriptan succinate) Injection 6mg administered using the STATdose system compared with an IMITREX tablet 100mg followed by an IMITREX tablet 100mg Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00875784 Clinicaltrials.gov link: https://clinicaltrials.gov/ct2/show/NCT00875784 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 1 Study Recruitment Status: Completed Generic Name: sumatriptan Trade Name: Imitrex ,Imiject ,Imigran; Imitrex,Imiject,Imigran Study Indication: Migraine Disorders

Lien

https://clinicaltrials.gov/ct2/show/NCT00875784

Mots-clés

Versions (2)

1. 18/11/2018 18/11/2018 -
2. 21/11/2018 21/11/2018 -

Détendeur de droits

GlaxoSmithKline

Téléchargé le

21 novembre 2018

DOI

Pour une demande vous connecter.

Licence